| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Melanocortin receptors (MC1-MC5)
|
|---|---|
| ln Vitro |
Adrenocorticotropic hormone (ACTH) is a tropic hormone that is secreted by the anterior pituitary. It controls the production of androgen and cortisol and is linked to Cushing syndrome, Addison's illness, and Cushing disease[1].
As a fragment of ACTH, it promotes the release of cortisol. ACTH (1-14) (TFA) is used in in vitro studies to investigate the structure-activity relationship of the melanocortin system and its role in steroidogenesis. |
| ln Vivo |
Adrenocorticotropic hormone is a tropic hormone secreted by the anterior pituitary that controls the production of androgens and cortisol. As a fragment of ACTH, this peptide plays a key role in the hypothalamic-pituitary-adrenal (HPA) axis by stimulating the adrenal cortex to produce and release cortisol, a primary stress hormone.
|
| Enzyme Assay |
In a standard receptor binding assay, the experimental compound is first dissolved in an appropriate buffer. Membrane preparations containing the target melanocortin receptors (e.g., MC2R) are incubated with a radiolabeled ligand (e.g., [125I]-ACTH) in the presence of varying concentrations of the test peptide. After incubation, the mixture is vacuum-filtered through glass fiber filters. The filters are washed, and the bound radioactivity is measured to determine the IC50 or Ki values.
|
| Cell Assay |
For in vitro assays, adrenocortical cells (e.g., from beef adrenal cortex) are freshly isolated or cultured. The cells are treated with various concentrations of ACTH (1-14) (TFA). After a defined incubation period, the culture medium is collected, and the concentration of cortisol is measured using an ELISA kit or a radioimmunoassay (RIA) to assess the peptide's ability to promote steroidogenesis.
|
| Animal Protocol |
In a typical in vivo experiment, male laboratory mice are injected with ACTH (1-14) (TFA) intraperitoneally or intravenously. Blood samples are collected at different time points post-injection. The plasma is separated, and corticosterone (the primary glucocorticoid in rodents) levels are measured using an ELISA kit. The peptide's effect on fighting behavior is also observed and scored.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for ACTH (1-14) TFA are not publicly available. As a short peptide fragment, it is likely susceptible to rapid degradation by proteolytic enzymes in vivo, leading to a short biological half-life. Its pharmacokinetics are presumed to be similar to that of native ACTH, which has a plasma half-life of about 10-20 minutes and is rapidly cleared from the circulation.
|
| Toxicity/Toxicokinetics |
No detailed toxicological profile is available for this specific research compound. Given its role in promoting cortisol release, chronic or excessive dosing could lead to hypercortisolism, which has systemic side effects including weight gain, immunosuppression, and osteoporosis. Standard safety precautions for handling research peptides should be followed.
|
| References | |
| Additional Infomation |
This peptide is a fragment of ACTH, a hormone that is part of the HPA axis. ACTH is clinically used as a diagnostic tool to assess adrenal function. ACTH (1-14) TFA is used in research to dissect the functional domains of ACTH. It is not approved for human therapeutic use and is strictly a research chemical.
|
| Molecular Formula |
C79H110F3N21O22S
|
|---|---|
| Molecular Weight |
1794.90
|
| Related CAS # |
ACTH (1-14);25696-21-3
|
| Appearance |
Solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~100 mg/mL (~55.71 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 25 mg/mL (13.93 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.5571 mL | 2.7857 mL | 5.5713 mL | |
| 5 mM | 0.1114 mL | 0.5571 mL | 1.1143 mL | |
| 10 mM | 0.0557 mL | 0.2786 mL | 0.5571 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
